Evaluation of adrenal masses with gadolinium enhancement and fat-suppressed MR imaging.
A study was undertaken to determine the ability to characterize benign and malignant masses with unenhanced and contrast material-enhanced fast low-angle shot and fat-suppressed spin-echo magnetic resonance (MR) imaging. Thirty patients with adrenal masses detected at computed tomography (CT) underwent MR imaging within 14 days after CT. CT and MR images were interpreted in a prospective, blinded fashion. Sixteen patients had 20 benign adrenal masses, and 14 patients had 18 malignant masses. Quantitative measurements included percentage of contrast enhancement on immediate postcontrast dynamic images and periphery--center signal-to-noise ratio (S/N) on gadolinium-enhanced fat-suppressed images. Qualitative evaluation included determination of the regularity of lesion margins, homogeneity of signal intensity, and local extension. MR imaging depicted all adrenal masses discovered at CT examinations. Lesions ranged in diameter from 1 to 15 (mean, 4.4) cm. No significant difference was observed in percentage of contrast enhancement between benign (90.5% +/- 59.0 [standard deviation]) and malignant (110.5% +/- 116.4) masses. A difference was observed between periphery--center S/N for benign (-.05 +/- 1.5) and malignant (7.7 +/- 9.8) masses; overlap between the two, however, occurred. Qualitative evaluation allowed correct characterization of 32 of 38 masses, comparing favorably with CT, which allowed characterization of 30 lesions.
Semelka
R C
RC
Department of Radiology, St Boniface General Hospital MRI Facility, Winnipeg, Manitoba, Canada.
Shoenut
J P
JP
Lawrence
P H
PH
Greenberg
H M
HM
Maycher
B
B
Madden
T P
TP
Kroeker
M A
MA
D000236:Adenoma / Q000175:diagnosis / Q000000981:diagnostic imaging; D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging; D000311:Adrenal Glands / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003287:Contrast Media; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D004369:Pentetic Acid; D011446:Prospective Studies; D014057:Tomography, X-Ray Computed
D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D019786:Gadolinium DTPA